Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 20/20 | 0.66 |
| ▸ | CD274 | Q9NZQ7 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20321427 | 0.87 | PDCD1 (0.59) | PDCD1CD274 | |
| SCHEMBL20293711 | 0.87 | PDCD1 (0.67) | PDCD1CD274 | |
| SCHEMBL20293681 | 0.86 | PDCD1 (0.90) | PDCD1CD274 | |
| SCHEMBL31137970 | 0.86 | PDCD1 (0.90) | PDCD1CD274 | |
| SCHEMBL20321337 | 0.85 | PDCD1 (0.72) | PDCD1CD274 | |
| SCHEMBL24722395 | 0.83 | PDCD1 (0.81) | PDCD1CD274 | |
| SCHEMBL23198464 | 0.83 | PDCD1 (0.84) | PDCD1CD274 | |
| SCHEMBL20293726 | 0.83 | PDCD1 (0.58) | PDCD1CD274 | |
| SCHEMBL20293727 | 0.83 | PDCD1 (0.58) | PDCD1CD274 | |
| SCHEMBL20304874 | 0.83 | PDCD1 (0.58) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11465981-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-10-11 | — | — | US | claimed |
| EP-3558973-B1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-09-15 | — | — | EP | claimed |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | claimed |
| US-11465981-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3558973-B1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3558973-B1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20200325115-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-10-15 | — | — | US | disclosed |
| US-20200325115-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-10-15 | — | — | US | disclosed |
| EP-3558973-A1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2018119221-A1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119221-A1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325115-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885 |
| US-11465981-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885 |
| US-20180179179-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.